Sugi Predict

Sugi Predict / Compounds / SCHEMBL2037115

SCHEMBL2037115

SCHEMBL2037115

CC(C)(C)OC(=O)CCCCCCCCCCCCCCCCCC(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 6/20 0.52
▸ LMNA P02545 2/20 0.52
▸ NFKB1 P19838 1/20 0.52
▸ PMP22 Q01453 1/20 0.52
▸ ALDH1A1 P00352 3/20 0.48
▸ GPR84 Q9NQS5 8/20 0.48
▸ PPARG P37231 7/20 0.48
▸ PPARD Q03181 7/20 0.48
▸ PPARA Q07869 7/20 0.48
▸ HDAC11 Q96DB2 5/20 0.48
▸ PTPN1 P18031 3/20 0.48
▸ TLR2 O60603 2/20 0.48
▸ TDP1 Q9NUW8 2/20 0.48
▸ FABP4 P15090 2/20 0.48
▸ FFAR1 O14842 2/20 0.48
▸ FFAR4 Q5NUL3 2/20 0.48
▸ SLC22A6 Q4U2R8 1/20 0.48
▸ SLC22A8 Q8TCC7 1/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ ESR1 P03372 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL417894 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22ALDH1A1
SCHEMBL2183805 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22ALDH1A1
SCHEMBL16342359 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22ALDH1A1
SCHEMBL16323109 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22ALDH1A1
SCHEMBL557403 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22ALDH1A1
SCHEMBL25176741 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22ALDH1A1
SCHEMBL414546 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22ALDH1A1
SCHEMBL2182221 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22ALDH1A1
SCHEMBL20897215 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22ALDH1A1
SCHEMBL28595399 1.00 TSHR (0.52) TSHRLMNANFKB1PMP22ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132182-A1 CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS NOVO NORDISK AS (DK) 2026-05-14 — — US disclosed
EP-4719486-A1 CONJUGATES AND USES THEREOF Full-Life Technologies UK Limited (GB) 2026-04-08 — — EP disclosed
EP-4719498-A1 RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF Full-Life Technologies UK Limited (GB) 2026-04-08 — — EP disclosed
US-20250270248-A1 OLIGONUCLEOTIDES CONJUGATED TO FATTY ACIDS ASTRAZENECA AB (SE) 2025-08-28 — — US disclosed
WO-2025098422-A1 MULTI-RECEPTOR CO-AGONIST COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF 深圳信立泰药业股份有限公司 2025-05-15 — — WO disclosed
US-20250099632-A1 CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF FULL-LIFE TECHNOLOGIES UK LIMITED (GB) 2025-03-27 — — US disclosed
US-12214059-B2 Cleavable radioligands for targeting cell surface receptors and uses thereof FULL-LIFE TECHNOLOGIES HK LIMITED (CN) 2025-02-04 — — US disclosed
WO-2024245407-A1 CONJUGATES AND USES THEREOF FULL-LIFE TECHNOLOGIES HK LIMITED (CN) 2024-12-05 — — WO disclosed
WO-2024245421-A1 RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF FULL-LIFE TECHNOLOGIES HK LIMITED (CN) 2024-12-05 — — WO disclosed
US-20240382630-A1 CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF FULL-LIFE TECHNOLOGIES UK LIMITED (GB) 2024-11-21 — — US disclosed
EP-2513140-A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES Novo Nordisk A/S (DK) 2012-10-24 — — EP disclosed
EP-2512518-A1 GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS Novo Nordisk A/S (DK) 2012-10-24 — — EP disclosed
EP-2513141-A2 GLP-1 ANALOGUES AND DERIVATIVES Novo Nordisk A/S (DK) 2012-10-24 — — EP disclosed
WO-2012140117-A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK A/S (DK) 2012-10-18 — — WO disclosed
WO-2012062803-A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK A/S (DK) 2012-05-18 — — WO disclosed
WO-2012062804-A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER NOVO NORDISK A/S (DK) 2012-05-18 — — WO disclosed
WO-2011080102-A2 GLP-1 ANALOGUES AND DERIVATIVES NOVO NORDISK A/S (DK) 2011-07-07 — — WO disclosed
WO-2011080103-A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK A/S (DK) 2011-07-07 — — WO disclosed
US-20110166321-A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK A/S (DK) 2011-07-07 — — US disclosed
WO-2011073328-A1 GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS NOVO NORDISK A/S (DK) 2011-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240382630-A1 CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF ASGR1, GNRHR, SCTR TSHR 17/4885LMNA 1407/4885NFKB1 3197/4885
US-20110166321-A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES GLP1R, IAPP, GCG TSHR 829/4885LMNA 3140/4885NFKB1 3269/4885
US-20260132182-A1 CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS GLP1R, GCGR, GIPR TSHR 250/4885LMNA 3349/4885NFKB1 2929/4885
US-12214059-B2 Cleavable radioligands for targeting cell surface receptors and uses thereof ASGR1, GNRHR, SCTR TSHR 17/4885LMNA 1407/4885NFKB1 3197/4885
US-20250099632-A1 CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF ASGR1, GNRHR, SCTR TSHR 17/4885LMNA 1407/4885NFKB1 3197/4885
US-20250270248-A1 OLIGONUCLEOTIDES CONJUGATED TO FATTY ACIDS FABP1, FABP3, ELOVL3 TSHR 1528/4885LMNA 1270/4885NFKB1 2900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.